Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Evidence shows pausing BTKi therapy for COVID-19 vaccination does not affect antibody responses to the vaccine ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Reports revenue RMB 980.7M vs. RMB 221.9M last year. Dajun Yang, CEO, said, “As we reflect on our achievements in 2024, I am delighted to ...

Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...